Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer.
Diamandis
E P
EP
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000494:pharmacology*; D017430:Prostate-Specific Antigen / Q000096:biosynthesis / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology*; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000187:drug effects
D018931:Antineoplastic Agents, Hormonal; D045167:Progesterone Congeners; D017430:Prostate-Specific Antigen; D019290:Megestrol Acetate